Kao J H, Wu N H, Chen P J, Lai M Y, Chen D S
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei.
J Hepatol. 2000 Dec;33(6):998-1002. doi: 10.1016/s0168-8278(00)80135-x.
BACKGROUND/AIMS: Possible pathogenic differences among hepatitis B virus (HBV) genotypes have been observed; however, the response to interferon therapy among HBV genotypes remains unknown. We therefore analyzed the efficacy of interferon alfa in the treatment of chronic hepatitis B patients with different HBV genotypes.
Fifty-eight genotype B or C infected chronic hepatitis B patients who had been treated with interferon alfa-2b were retrospectively studied. The response to interferon was defined as normalization of serum aminotransferase level, loss of hepatitis B e antigen and HBV DNA 48 weeks post-treatment.
Baseline data of both groups of patients were comparable; however, genotype C patients had a higher serum aminotransferase level and a higher frequency of core promoter mutation. The response rate was 41% and 15% in genotype B and C patients, respectively (p=0.045). In those with higher serum aminotransferase levels, the response rate was 50% and 17%, respectively (p=0.025). Additionally, younger age and genotype B infection may predict a better response to interferon alfa.
HBV genotype C, compared to genotype B, is associated with a higher frequency of core promoter mutation, and a lower response rate to interferon alfa therapy.
背景/目的：已观察到乙肝病毒（HBV）基因型之间可能存在致病性差异；然而，HBV各基因型对干扰素治疗的反应仍不清楚。因此，我们分析了α干扰素治疗不同HBV基因型慢性乙型肝炎患者的疗效。
回顾性研究了58例接受α-2b干扰素治疗的B或C基因型感染的慢性乙型肝炎患者。对干扰素的反应定义为治疗48周后血清转氨酶水平正常化、乙肝e抗原消失及HBV DNA转阴。
两组患者的基线数据具有可比性；然而，C基因型患者血清转氨酶水平较高，核心启动子突变频率较高。B和C基因型患者的反应率分别为41%和15%（p=0.045）。在血清转氨酶水平较高的患者中，反应率分别为50%和17%（p=0.025）。此外，年龄较小和B基因型感染可能预示对α干扰素的反应较好。
与B基因型相比，C基因型HBV与核心启动子突变频率较高及对α干扰素治疗的反应率较低有关。
Zotero 插件